Contrast-enhanced ultrasound may avert prostate biopsies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies.

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies. They found generally that contrast ultrasound provided more precise locational information than is available with unenhanced grayscale ultrasound. Biopsies based on the contrast scans resulted in a sensitivity of 85.2%, according to the group from the Medical University of Innsbruck (European Congress of Radiology 2009 abstract C-390).

A group at Shanghai’s Jio Tong University used microflow imaging and found a sensitivity of 80% and an accuracy of 83% for this contrast strategy. However, limitations included cost and training (abstract C-391).

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content